

Does the use of quit smoking medicines in early pregnancy increase the risk of adverse outcomes for the mother or baby?

Tran DT¹, Donald S², Cohen JM³, Cesta CE⁴, Furu K³, Parkin L^{2,5}, Pearson S⁶, Reutfors J⁴, Robijn AL¹, Zoega H⁷, Brew BK⁸, McNamara K⁹, Zwar N¹⁰, Havard A^{1,6}

The Difference is Research

Background

Nicotine replacement therapy, varenicline, and bupropion are the most effective strategies for smoking cessation. However, evidence on their safety during pregnancy remains limited.

Aims

To examine whether using a nicotine replacement therapy, varenicline, and bupropion in early pregnancy increases the risk of pregnancy adverse outcomes compared to maternal smoking alone.

Methods

Setting


Data linkage

Population

Exposure status


Confounding adjustment

Analyses



Results

Below are results among NSW cohort. Analyses among cohorts in New Zealand, Norway and Sweden are under-way.



Conclusion

Nicotine patch or varenicline was not clearly associated with an increased risk of adverse maternal and baby outcomes.